New Positive Efficacy Data for Efti in Head and Neck Cancer
Filed with ASX · · 4 pages · English and French
In the deck
Story so far
Earlier from Immutep
- S&P DJI Announces September 2024 Quarterly Rebalance
- Appendix 4E & 2024 Full Year Statutory Accounts
- TACTI-003 data selected for oral presentation at ESMO 2024
- First Participant Dosed in Phase I Study of IMP761
- Successful Meeting with FDA on Phase III Design in NSCLC
Later from Immutep
- Immutep receives A$3.6 million French R&D Tax Incentive
- Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed
- Positive Data from Phase II Trial in Soft Tissue Sarcoma
- Excellent Survival Data from INSIGHT-003 Trial in NSCLC
- Initiation of TACTI-004 phase 3 trial in 1st line NSCLC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep